The rise of anti-obesity drugs, especially GLP-1 medications like Wegovy and Mounjaro, has sparked a debate about their role in weight loss. As India’s anti-obesity drug market is expected to grow rapidly, with projections reaching ₹25,000 crore by 2030, these drugs have become a common solution for people struggling with obesity. But the question remains: are they necessary for everyone, or are they a quick fix for deeper health issues?
GLP-1 drugs are designed to target chronic metabolic conditions like obesity and diabetes, especially when diet and exercise are not enough. However, the widespread use of these drugs raises concerns about their potential side effects and who should actually consider taking them. For people with high visceral fat, which surrounds organs like the liver and kidneys, GLP-1 drugs can help reduce fat and manage insulin resistance, which is crucial for preventing diabetes.
Understanding Obesity: More Than Just BMI
Body Mass Index (BMI) has long been used to measure obesity, but it doesn’t tell the whole story. BMI fails to account for factors like muscle mass or fat distribution. Instead, doctors recommend measuring waist-to-hip ratios, particularly for South Asians. A waist-to-hip ratio greater than 0.9 for men or 0.8 for women can signal potential health risks.
For those truly struggling with obesity, clinical methods like DEXA scans or skinfold tests are more accurate indicators of fat levels. While a BMI of 26 might suggest a person is overweight, someone with the same BMI might have a dangerously high body fat percentage concentrated around the belly—often referred to as the “skinny fat” phenomenon.
Visceral fat, hidden deep inside the body, is the main culprit behind serious health issues like insulin resistance and diabetes. Even if you don’t appear overweight, high levels of visceral fat can make you unfit. In these cases, GLP-1 drugs may be an effective solution to reduce fat and improve overall health.
Should You Consider GLP-1 Drugs?
While GLP-1 drugs like Mounjaro and Wegovy offer hope to many, they come at a significant cost. In India, Mounjaro’s price ranges from ₹3,500 to ₹4,375 per vial, while Wegovy pre-filled pens can cost up to ₹26,015 monthly. Although generics are expected to emerge soon, these drugs are not cosmetic solutions; they are intended for individuals who need medical intervention for obesity or diabetes. Before considering GLP-1 drugs, it’s important to consult an endocrinologist or obesity specialist. They will evaluate your body fat percentage, lifestyle habits, and metabolic history to determine whether these medications are appropriate for you.
